title: Development of plaque assays for adenoviruses 40 and 41.
abstract: Enteric adenoviruses, important agents of infantile gastroenteritis, are difficult to culture with low titers and limited CPE. Consequently, few plaque assays have been reported and none are used routinely by investigators who may need reproducible quantitative assays for these viruses. CPE in A549 cells (an epithelial lung carcinoma cell line) was induced by isolates of human adenovirus (HAdV) serotypes 40 or 41 that were obtained by prior limited passage in primary cynmolgous monkey kidney (pCMK), human embryonic kidney (HEK), and Graham 293 cells. CPE with HAdV 40 (Dugan strain) and HAdV 41 (Tak strain) inoculated in A549 cells was also observed. Monolayers of A549 cells were inoculated with a low multiplicity of infection (MOI) of the archived stock isolates and harvested at days 10-14 with full CPE. Subsequent passages were harvested in as few as 7 days with 100% CPE to prepare virus stocks for plaque assay. Large individual plaques under agarose overlay were picked prior to staining and clonal stocks prepared. Titers of final stock preparations after six to eight passages in A549 cells were in the range of 5 x 10(7)-1 x 10(8)PFU/ml, which provides adequate virus for quantitative recovery studies. The particle to infectivity (P:I) ratios of the early passages of virus stocks were in the range reported previously. The ratio of non-infectious to infectious particles decreased with successive passages of HAdVs 40 and 41 in A549 cells. The specificity of the assay was confirmed by neutralization of plaques with type-specific antisera. Furthermore, sequence analysis of the HAdVs 40 and 41 plaque forming stocks ruled out contamination with any other HAdVs. The plaque assay developed will be useful for evaluation of virus recovery methods from water, food or other environmental matrices, as well as determination of the efficacy of water treatment techniques for inactivation of these viruses.
authors.affiliation: Atlanta Research and Education Foundation, Atlanta, GA, United States. trc1@cdc.gov
authors.forename: Theresa L
authors.initials: TL
authors.lastname: Cromeans
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Lu
authors.forename: Dean D
authors.initials: DD
authors.lastname: Erdman
authors.forename: Charles D
authors.initials: CD
authors.lastname: Humphrey
authors.forename: Vincent R
authors.initials: VR
authors.lastname: Hill
mesh_terms: D000258:Adenovirus Infections, Human / Q000821:virology*; D000260:Adenoviruses, Human / Q000145:classification / Q000302:isolation & purification / Q000472:pathogenicity* / Q000648:ultrastructure; D000818:Animals; D045744:Cell Line, Tumor; D003588:Cytopathogenic Effect, Viral; D004847:Epithelial Cells / Q000648:ultrastructure / Q000821:virology*; D005759:Gastroenteritis / Q000821:virology*; D006801:Humans; D008168:Lung / Q000166:cytology / Q000821:virology*; D008854:Microscopy, Electron; D012680:Sensitivity and Specificity; D012703:Serotyping; D010948:Viral Plaque Assay / Q000379:methods*; D014773:Virology / Q000379:methods